US Market News
3週前
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior NotesJune 17, 2026 6:00 AM
Business Wire NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million aggregate principal amount of 0.75% convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In addition, NeoGenomics granted the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $41.25 million aggregate principal amount of the notes. The offering is expected to close on June 22, 2026, subject to customary closing conditions. The notes will be senior, unsecured obligations of NeoGenomics and will bear interest at a rate of 0.75% per year payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2027. The notes will mature on July 1, 2032, unless earlier converted, redeemed or repurchased. Before April 1, 2032, noteholders will have the right to convert their notes in certain circumstances and during specified periods. From and after April 1, 2032, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. NeoGenomics will settle conversions by paying or delivering, as applicable, cash, shares of its common stock, par value $0.001 per share (“common stock”), or a combination of cash and shares of its common stock, at NeoGenomics’ election. The initial conversion rate is 70.6140 shares of common stock per $1,000 principal amount of the notes, which represents an initial conversion price of approximately $14.16 per share of NeoGenomics’ common stock. The initial conversion price represents a premium of approximately 35% to the last reported sale price of $10.49 per share of the common stock on The Nasdaq Capital Market on June 16, 2026. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at NeoGenomics’ option at any time, and from time to time, on or after July 6, 2029 and on or before the 51st scheduled trading day immediately preceding the maturity date, if the last reported sale price per share of NeoGenomics’ common stock equals or exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, the notes will be redeemable at any time if the aggregate principal amount of the notes that remains outstanding is less than 15% of the aggregate principal amount of the notes initially issued in the offering and certain other conditions are satisfied. In connection with the pricing of the notes, NeoGenomics entered into privately negotiated capped call transactions with certain financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce potential dilution to NeoGenomics’ common stock upon conversion of any notes and/or offset any potential cash payments NeoGenomics is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions will initially be $20.98 per share of NeoGenomics’ common stock, which represents a premium of 100% to the last reported sale price of $10.49 per share of the common stock on The Nasdaq Capital Market on June 16, 2026. NeoGenomics has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of NeoGenomics’ common stock and/or enter into various derivative transactions with respect to NeoGenomics’ common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock or the notes at that time. In addition, the option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to NeoGenomics’ common stock and/or purchasing or selling NeoGenomics’ common stock or other securities of NeoGenomics in secondary market transactions from time to time prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes or following certain repurchases or redemptions of the notes). This activity could cause or avoid an increase or a decrease in the market price of NeoGenomics’ common stock or the notes, which could affect the ability of holders to convert the notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of notes, it could affect the amount and value of the consideration that holders will receive upon conversion of such notes. NeoGenomics estimates that the net proceeds from the offering of the notes will be approximately $266.15 million (or approximately $306.16 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses payable by NeoGenomics. NeoGenomics intends to use approximately $25 million of the net proceeds from the offering to pay the cost of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, NeoGenomics expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions. In addition, NeoGenomics intends to use a portion of the net proceeds from the offering, together with cash on hand, to repurchase for cash $276 million aggregate principal amount of NeoGenomics’ 0.25% convertible senior notes due 2028 (the “existing notes”) through privately negotiated transactions entered into concurrently with the pricing of the notes effected through one or more of the initial purchasers or their affiliates as our agents, and the remaining net proceeds from the offering, if any, together with cash on hand, to repurchase up to an aggregate of $25 million of our outstanding shares of common stock from certain purchasers of notes in privately negotiated transactions, effected through one or more of the initial purchasers or their respective affiliates as our agent, entered into concurrently with the closing of this offering, and the remainder of the net proceeds, if any, for general corporate purposes. The concurrent repurchases of the existing notes and shares of the Company’s common stock described above may result in the Company’s common stock trading at prices that are higher than would be the case in the absence of these repurchases, which may result in a higher initial conversion price for the notes to be offered. Concurrently with the pricing of the notes, NeoGenomics entered into privately negotiated transactions (the “note repurchase transactions”) with certain holders of the existing notes to repurchase for cash $276 million aggregate principal amount of the existing notes for a total repurchase cost (including accrued and unpaid interest) of approximately $263.19 million. The terms of the note repurchase transactions were individually negotiated with certain holders of the existing notes and depended on a variety of factors, including the market price of NeoGenomics’ common stock and the trading price of the existing notes. This press release is not an offer to repurchase the existing notes, and the offering of the notes is not contingent upon the repurchase of the existing notes. In connection with the note repurchase transactions, NeoGenomics expects that holders of the existing notes who have agreed to have their existing notes repurchased and who have hedged their equity price risk with respect to such existing notes (the “hedged holders”) will unwind all or part of their hedge positions by buying NeoGenomics’ common stock and/or entering into or unwinding various derivative transactions with respect to NeoGenomics’ common stock. The amount of NeoGenomics’ common stock to be purchased by the hedged holders or the notional number of shares of NeoGenomics’ common stock underlying such derivative transactions may be substantial in relation to the historic average daily trading volume of NeoGenomics’ common stock. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes. NeoGenomics cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or NeoGenomics’ common stock and the corresponding effect on the initial conversion price of the notes. The notes were offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. About NeoGenomics NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the U.S. and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements, which include those concerning whether NeoGenomics will issue the notes; whether the note repurchase transactions will settle; whether the common stock repurchase transactions will settle; the anticipated use of the net proceeds from the offering; expectations regarding the effect of the capped call transactions; expectations regarding actions of the hedged holders, the option counterparties and their respective affiliates; and whether the capped call transactions will become effective, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, risks with respect to the market acceptance of the Company’s products and services, as well as the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission (SEC). We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20260617584382/en/ Investor Contact
InvestorRelations@neogenomics.com Media Contact
Andrea Sampson
asampson@sampsonprgroup.com Original: NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
US Market News
3週前
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior NotesJune 15, 2026 5:24 PM
Business Wire NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering, NeoGenomics expects to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $41.25 million aggregate principal amount of the notes. The offering of the notes is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The notes will be senior, unsecured obligations of NeoGenomics, will accrue interest payable semi-annually in arrears and will mature on July 1, 2032, unless earlier converted, redeemed or repurchased. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. NeoGenomics will settle conversions by paying or delivering, as applicable, cash, shares of its common stock, par value $0.001 per share (“common stock”), or a combination of cash and shares of its common stock, at NeoGenomics’ election. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at NeoGenomics’ option at any time, and from time to time, on or after July 6, 2029 and on or before the 51st scheduled trading day immediately preceding the maturity date, if the last reported sale price per share of NeoGenomics’ common stock equals or exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, the notes will be redeemable at any time if the aggregate principal amount of the notes that remains outstanding is less than 15% of the aggregate principal amount of the notes initially issued in the offering and certain other conditions are satisfied. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering. In connection with the pricing of the notes, NeoGenomics expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their respective affiliates or other financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce potential dilution to NeoGenomics’ common stock upon conversion of any notes and/or offset any potential cash payments NeoGenomics is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. NeoGenomics has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of NeoGenomics’ common stock and/or enter into various derivative transactions with respect to NeoGenomics’ common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock or the notes at that time. In addition, the option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to NeoGenomics’ common stock and/or purchasing or selling NeoGenomics’ common stock or other securities of NeoGenomics in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes or following certain repurchases or redemptions of the notes). This activity could cause or avoid an increase or a decrease in the market price of NeoGenomics’ common stock or the notes, which could affect the ability of holders to convert the notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of notes, it could affect the amount and value of the consideration that holders will receive upon conversion of such notes. NeoGenomics intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, NeoGenomics expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions. In addition, NeoGenomics intends to use a portion of the remaining net proceeds from the offering, together with cash on hand, to repurchase a portion of NeoGenomics’ 0.25% convertible senior notes due 2028 (the “existing notes”) through privately negotiated transactions entered into concurrently with the pricing of the notes effected through one or more of the initial purchasers or their affiliates as our agents, and a portion of the remaining net proceeds from the offering, if any, together with cash on hand, to repurchase up to $25 million of shares of our outstanding common stock from certain purchasers of the notes in privately negotiated transactions, effected through one or more of the initial purchasers or their respective affiliates as our agent, entered into concurrently with the pricing of this offering, and the remainder of the net proceeds, if any, for general corporate purposes. The concurrent repurchases of the existing notes and shares of Company’s common stock described above may result in the Company’s common stock trading at prices that are higher than would be the case in the absence of these repurchases, which may result in a higher initial conversion price for the notes to be offered. NeoGenomics expects to repurchase for cash a portion of the existing notes through privately negotiated transactions (the “note repurchase transactions”) entered into concurrently with the pricing of the notes. The terms of each note repurchase transaction will depend on a variety of factors, including the market price of NeoGenomics’ common stock and the trading price of the existing notes at the time of the note repurchase transactions. No assurance can be given as to how much, if any, of the existing notes will be repurchased or the terms on which they will be repurchased. This press release is not an offer to repurchase the existing notes, and the offering of the notes is not contingent upon the repurchase of the existing notes. In connection with the note repurchase transactions, NeoGenomics expects that holders of the existing notes who agree to have their existing notes repurchased and who have hedged their equity price risk with respect to such existing notes (the “hedged holders”) will unwind all or part of their hedge positions by buying NeoGenomics’ common stock and/or entering into or unwinding various derivative transactions with respect to NeoGenomics’ common stock. The amount of NeoGenomics’ common stock to be purchased by the hedged holders or the notional number of shares of NeoGenomics’ common stock underlying such derivative transactions may be substantial in relation to the historic average daily trading volume of NeoGenomics’ common stock. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of NeoGenomics’ common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes. NeoGenomics cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or NeoGenomics’ common stock and the corresponding effect on the initial conversion price of the notes. The notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. About NeoGenomics NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the U.S. and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements, which include those concerning NeoGenomics’ future expectations, plans and prospects, including, without limitation, statements regarding: whether NeoGenomics will offer and issue the notes and the terms of the notes; whether NeoGenomics will repurchase any existing notes or shares of outstanding common stock and the terms of any repurchase transactions; the anticipated use of the net proceeds from the offering; expectations regarding the effect of the capped call transactions; expectations regarding actions of the hedged holders, the option counterparties and their respective affiliates; and whether the capped call transactions will become effective and the terms of the capped call transactions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, risks with respect to the market acceptance of the Company’s products and services, as well as the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission (SEC). We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20260615452524/en/ Investor Contact
InvestorRelations@neogenomics.com Media Contact
Andrea Sampson
asampson@sampsonprgroup.com Original: NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
US Market News
2月前
NeoGenomics Reports First Quarter 2026 ResultsApril 28, 2026 4:05 PM
Business Wire
First quarter total revenue increased 11% YoY to $187 million;
Clinical revenue grew 14%, including NGS growth of 26%;
Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million
NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first quarter results for the period ended March 31, 2026.
First Quarter 2026 Financial Highlights As Compared To First Quarter 2025
Consolidated revenue increased 11% to a first quarter record $187 million, driven by Clinical revenue growth of 14%
Net loss decreased 34% to $17 million
Adjusted EBITDA(1) was positive $9 million, an increase of 27% from prior year
First Quarter 2026 Operating Highlights
Launched RaDaR® ST, a circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD), which we estimate represents a $20 billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated.
Announced a favorable MolDX coverage decision for PanTracer™ LBx, its blood-based comprehensive genomic profiling (CGP) test designed to support therapy selection and clinical trial enrollment in patients with advanced solid tumors.
Introduced PanTracer Pro, a new addition to the PanTracer® Family, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patients with advanced-stage solid tumors.
“The first quarter of 2026 was a truly transformational one for NeoGenomics. We again delivered double-digit revenue growth while making meaningful strides in our efforts to bring the latest innovation in advanced cancer testing to the community setting,” stated Tony Zook, Chief Executive Officer of NeoGenomics. “The full clinical launch of our RaDaR® ST MRD assay in February represents an important advancement in residual disease monitoring, which we estimate represents a $20 billion addressable market that is underpenetrated and growing rapidly. Additionally, we believe the receipt of MolDX reimbursement coverage for PanTracer LBx and the launch of PanTracer Pro addresses a significant need among our customers and complements our PanTracer Tissue offering, which has seen robust growth in test volumes over the past two years. These important additions further differentiate our portfolio, advancing our objective to deliver long-term predictable revenue growth while helping community providers achieve optimal outcomes for their patients.”
First-Quarter Results
Consolidated revenue for the first quarter of 2026 was $187 million, an increase of 11% over the same period in 2025. Average revenue per clinical test increased by 8% to $495 with 9% growth excluding recently acquired Pathline tests.
Consolidated gross profit for the first quarter of 2026 was $81 million, an increase of 10% compared to the first quarter of 2025. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based compensation expense, was 43%. Adjusted Gross Profit Margin(1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 46%.
Operating expenses for the first quarter of 2026 were $99 million, a decrease of $2 million, or 2%, compared to the first quarter of 2025.
Net loss for the quarter decreased by $9 million, or 34%, to $17 million compared to net loss of $26 million for the first quarter of 2025.
Adjusted EBITDA(1) for the first quarter of 2026 increased by 27% to $9.0 million, compared to $7.1 million in the first quarter of 2025. Adjusted Net Income(1) was $1.4 million compared to Adjusted Net Loss(1) of $0.5 million in the first quarter of 2025.
Cash and cash equivalents and marketable securities totaled $146 million at quarter end.
(1)
The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this press release entitled “Use of Non-GAAP Financial Measures.” See also the tables reconciling such measures to their closest GAAP equivalent.
2026 Financial Guidance
The Company revised its full-year 2026 guidance, as initially issued on February 17, 2026 (in millions).
FY 2025
Initial
FY 2026
Guidance
Revised
FY 2026
Guidance
YOY % Change from FY
2025
(in millions)
Actual
Low
High
Low
High
Low
High
Consolidated revenue
$727
$793
$801
$797
$803
10%
10%
Net loss
$(108)
$(63)
$(50)
$(63)
$(50)
42%
54%
Adjusted EBITDA
$43
$55
$57
$55
$57
27%
31%
Conference Call
The Company has scheduled a webcast and conference call to discuss its first quarter 2026 results on Tuesday, April 28, 2026 at 4:30 p.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 750346. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
We routinely post information that may be important to investors on our website at https://www.neogenomics.com. Information on, or accessible through, our website is not incorporated by reference into, and is not a part of, this release or any other report or document that we may file with the Securities and Exchange Commission (“SEC”).
Forward Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “enable,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include statements regarding the Company’s strategy, planned future operations and related expectations with respect to timing and performance, future financial position, future revenues, growth potential and expected growth drivers, projected costs and capital expenditures, prospects and plans, and estimates of market size and position, as well as statements regarding the design and expected capabilities of the Company's test offerings and the objectives of management. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to execute on its strategic priorities, to enter new markets and increase market share in both current and new markets, to assemble and maintain an effective executive team, to continue gaining new customers, develop and commercialize new types of tests, integrate its acquisitions, manage the effects of seasonality, execute on its long-range strategic priorities and otherwise implement its business plans, as well as the potential impact of evolving regulatory requirements related to laboratory developed tests, the impact of tariffs and trade policy uncertainty on the Company's supply chain and costs, and any potential reimbursement changes by the government and commercial payors, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and filed with the SEC on February 17, 2026, as well as subsequently filed Quarterly Reports on Form 10-Q and the Company's other filings with the SEC.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
NeoGenomics, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
March 31, 2026
(unaudited)
December 31, 2025
ASSETS
Current assets
Cash and cash equivalents
$
146,143
$
159,618
Accounts receivable, net
167,424
159,242
Inventories
29,837
28,566
Prepaid assets
23,666
21,443
Other current assets
6,614
7,417
Total current assets
373,684
376,286
Property and equipment, net
83,659
84,834
Operating lease right-of-use assets
76,703
78,444
Intangible assets, net
278,895
286,528
Goodwill
523,995
524,344
Other assets
9,595
9,394
Total non-current assets
972,847
983,544
Total assets
$
1,346,531
$
1,359,830
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and other current liabilities
$
79,762
$
83,524
Current portion of operating lease liabilities
4,828
4,776
Total current liabilities
84,590
88,300
Long-term liabilities
Operating lease liabilities
61,461
62,822
Convertible senior notes, net
342,240
341,858
Deferred income tax liabilities, net
17,450
18,219
Other long-term liabilities
12,030
12,069
Total long-term liabilities
433,181
434,968
Total liabilities
$
517,771
$
523,268
Stockholders’ equity
Total stockholders' equity
$
828,760
$
836,562
Total liabilities and stockholders’ equity
$
1,346,531
$
1,359,830
NeoGenomics, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)
Three Months Ended March 31,
2026
2025
NET REVENUE
$
186,672
$
168,035
COST OF REVENUE
105,808
94,789
GROSS PROFIT
80,864
73,246
Operating expenses:
General and administrative
65,741
68,207
Research and development
9,534
10,181
Sales and marketing
23,830
22,683
Total operating expenses
99,105
101,071
LOSS FROM OPERATIONS
(18,241
)
(27,825
)
Interest income
(1,273
)
(3,721
)
Interest expense
598
1,618
Other expense (income), net
12
(65
)
Loss before taxes
(17,578
)
(25,657
)
Income tax (benefit) expense
(472
)
266
NET LOSS
$
(17,106
)
$
(25,923
)
NET LOSS PER SHARE
Basic
$
(0.13
)
$
(0.20
)
Diluted
$
(0.13
)
$
(0.20
)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic
129,166
127,376
Diluted
129,166
127,376
NeoGenomics, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months Ended March 31,
2026
2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
$
(17,106
)
$
(25,923
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
8,780
9,366
Amortization of intangibles
7,633
8,362
Stock-based compensation
9,636
10,754
Non-cash operating lease expense
1,720
1,584
Other adjustments
402
772
Changes in assets and liabilities, net
(19,202
)
(30,242
)
Net cash used in operating activities
(8,137
)
(25,327
)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from maturities of marketable securities
—
8,060
Purchases of property and equipment
(5,000
)
(4,500
)
Net cash (used in) provided by investing activities
(5,000
)
3,560
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock, net
(338
)
949
Net cash (used in) provided by financing activities
(338
)
949
Net change in cash and cash equivalents
(13,475
)
(20,818
)
Cash and cash equivalents, beginning of period
159,618
367,012
Cash and cash equivalents, end of period
$
146,143
$
346,194
Use of Non-GAAP Financial Measures
The Company reports its financial results in accordance with generally accepted accounting principles in the United States (“GAAP”). However, in order to provide greater transparency regarding our operating performance, the financial results and financial guidance in this press release refer to certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to the Company’s core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of the Company’s core test-level operating results across reporting periods. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results and may exclude items that are significant to understanding and assessing the Company's financial results. Therefore, these measures should not be considered measures of liquidity or considered in isolation or as an alternative to other measures of the Company's profitability or performance under GAAP. The Company's presentation of non-GAAP financial measures is unlikely to be comparable to similarly-titled non-GAAP financial measures provided by other companies.
Definitions of Non-GAAP Financial Measures
Non-GAAP Adjusted EBITDA
“Adjusted EBITDA” is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest income, (ii) interest expense, (iii) income tax (benefit) or expense, (iv) depreciation and amortization expense, (v) stock-based compensation expense, and, if applicable in a reporting period, (vi) CEO transition costs, (vii) acquisition and integration related expenses, (viii) intellectual property (“IP”) litigation costs, and (ix) other significant or non-operating (income) or expenses, net.
Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin
“Adjusted cost of revenue” is defined by NeoGenomics as cost of revenue before: (i) amortization of acquired intangible assets, and (ii) stock-based compensation expense.
“Adjusted gross profit” is defined by NeoGenomics as total revenue less adjusted cost of revenue.
“Adjusted gross profit margin” is defined by NeoGenomics as adjusted cost of revenue divided by total revenue.
Non-GAAP Adjusted Net (Loss) Income
“Adjusted net (loss) income” is defined by NeoGenomics as net (loss) income from continuing operations plus: (i) amortization of intangible assets, (ii) stock-based compensation expense, and, if applicable in a reporting period, (iii) CEO transition costs, (iv) acquisition and integration related expenses, (v) IP litigation costs, and (vi) other significant or non-operating (income) or expenses, net. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method unless the effect of this adjustment on both the adjusted net (loss) income and weighted average diluted common shares outstanding would be anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method.
Non-GAAP Adjusted Diluted EPS
“Adjusted diluted EPS” is defined by NeoGenomics as adjusted net (loss) income divided by adjusted diluted shares outstanding. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted diluted shares outstanding will also include any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted diluted shares outstanding will exclude any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period.
The following tables present reconciliations of the Company's non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP.
Reconciliation of GAAP Net Loss to Non-GAAP EBITDA and Adjusted EBITDA
(in thousands)
(unaudited)
Three Months Ended March 31,
2026
2025
Net loss (GAAP)
$
(17,106
)
$
(25,923
)
Adjustments to net loss:
Interest income
(1,273
)
(3,721
)
Interest expense
598
1,618
Income tax (benefit) expense
(472
)
266
Depreciation
8,780
9,366
Amortization of intangibles
7,633
8,362
EBITDA (non-GAAP)
$
(1,840
)
$
(10,032
)
Further adjustments to EBITDA:
CEO transition costs(1)
—
2,193
Acquisition and integration related expenses(2)
806
1,172
Stock-based compensation expense
9,636
10,754
IP litigation costs(3)
—
2,983
Other significant expenses, net(4)
402
—
Adjusted EBITDA (non-GAAP)
$
9,004
$
7,070
_________________
(1)
For the three months ended March 31, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three months ended March 31, 2026.
(2)
For the three months ended March 31, 2026, acquisition and integration related expenses include severance costs. For the three months ended March 31, 2025, acquisition and integration related expenses include legal and consulting costs.
(3)
For the three months ended March 31, 2025, IP litigation costs include legal fees. There were no such costs for the three months ended March 31, 2026.
(4)
For the three months ended March 31, 2026, other significant (income) expenses, net, includes executive retention costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three months ended March 31, 2025.
Reconciliation of Consolidated GAAP Cost of Revenue, Gross Profit and Gross Profit Margin to
Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin
(dollars in thousands)
(unaudited)
Three Months Ended March 31,
2026
2025
% Change
Consolidated:
Total revenue (GAAP)
$
186,672
$
168,035
11.1
%
Cost of revenue (GAAP)
$
105,808
$
94,789
11.6
%
Adjustments to cost of revenue(1)
(4,951
)
(5,325
)
Adjusted cost of revenue (non-GAAP)
$
100,857
$
89,464
12.7
%
Gross profit (GAAP)
$
80,864
$
73,246
10.4
%
Adjusted gross profit (non-GAAP )
$
85,815
$
78,571
9.2
%
Gross profit margin (GAAP)
43.3
%
43.6
%
Adjusted gross profit margin (non-GAAP)
46.0
%
46.8
%
_______________
(1)
Cost of revenue adjustments for the three months ended March 31, 2026, includes $4.6 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Cost of revenue adjustments for the three months ended March 31, 2025, includes $4.9 million of amortization of acquired intangible assets and $0.4 million of stock-based compensation.
Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss
and GAAP EPS to Non-GAAP Adjusted EPS
(in thousands, except per share amounts)
(unaudited)
Three Months Ended March 31,
2026
2025
Net loss (GAAP)
$
(17,106
)
$
(25,923
)
Adjustments to net loss, net of tax:
Amortization of intangibles
7,633
8,362
CEO transition costs(1)
—
2,193
Acquisition and integration related expenses(2)
806
1,172
Stock-based compensation expense
9,636
10,754
IP litigation costs(3)
—
2,983
Other significant expenses, net(4)
402
—
Adjusted net income/(loss)
$
1,371
$
(459
)
Net loss per common share (GAAP)
Diluted EPS
$
(0.13
)
$
(0.20
)
Adjustments to diluted loss income per share:
Amortization of intangibles
0.06
0.07
CEO transition costs(1)
—
0.02
Acquisition and integration related expenses(2)
0.01
0.01
Stock-based compensation expense
0.07
0.08
IP litigation costs(3)
—
0.02
Other significant expenses, net(4)
0.01
—
Rounding and impact of diluted shares in adjusted diluted shares(5)
(0.01
)
—
Adjusted diluted EPS (non-GAAP)
$
0.01
$
—
Weighted average shares used in computation of adjusted diluted EPS:
Diluted common shares (GAAP)
129,166
127,376
Dilutive effect of options, restricted stock, and converted shares(6)(7)
—
—
Adjusted diluted shares outstanding (non-GAAP)
129,166
127,376
_______________
(1)
For the three months ended March 31, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three months ended March 31, 2026.
(2)
For the three months ended March 31, 2026, acquisition and integration related expenses include severance costs. For the three months ended March 31, 2025, acquisition and integration related expenses include legal and consulting costs.
(3)
For the three months ended March 31, 2025, IP litigation costs include legal fees. There were no such costs for the three months ended March 31, 2026.
(4)
For the three months ended March 31, 2026, other significant (income) expenses, net, includes executive retention costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three months ended March 31, 2025.
(5)
This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive or GAAP net (loss) income is positive and adjusted net (loss) income is negative, also compensates for the effects of additional diluted shares included or excluded in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes.
(6)
In those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive.
(7)
In those periods in which GAAP net (loss) income is positive and adjusted net (loss) income is negative, this adjustment excludes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period.
Reconciliation of Non-GAAP Financial Guidance to Corresponding GAAP Measures
(in thousands, except per share amounts)
(unaudited)
GAAP net loss in 2026 will be impacted by certain charges, including: (i) expense related to the amortization of intangible assets, (ii) stock-based compensation, and (iii) other one-time expenses. These charges have been included in GAAP net loss available to stockholders and GAAP net loss per share; however, they have been removed from adjusted net loss and adjusted diluted net loss per share.
The following table reconciles the Company’s 2026 outlook for net loss and EPS to the corresponding non-GAAP measures of adjusted net loss, adjusted EBITDA, and adjusted diluted EPS:
Year Ended December 31, 2026
Low Range
High Range
Net loss (GAAP)
$
(63,000
)
$
(50,000
)
Amortization of intangibles
30,000
30,000
Stock-based compensation expenses
43,000
40,000
Other one-time expenses
11,000
7,000
Adjusted net income (non-GAAP)
21,000
27,000
Interest and taxes
(5,000
)
(6,000
)
Depreciation
39,000
36,000
Adjusted EBITDA (non-GAAP)
$
55,000
$
57,000
Net loss per diluted share (GAAP)
$
(0.48
)
$
(0.38
)
Adjustments to net loss per diluted share:
Amortization of intangibles
0.23
0.23
Stock-based compensation expenses
0.33
0.31
Other one-time expenses
0.08
0.05
Rounding and impact of diluted shares in adjusted diluted shares(1)
—
—
Adjusted diluted EPS(1) (non-GAAP)
$
0.16
$
0.21
Weighted average assumed shares outstanding in 2026:
Diluted shares (GAAP)
130,000
130,000
Options, restricted stock, and converted shares not included in diluted shares(2)
—
—
Adjusted diluted shares outstanding (non-GAAP)
130,000
130,000
_________________
(1)
This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, also compensates for the effects of additional diluted shares included in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes.
(2)
For those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive.
Supplemental Information
Clinical Tests Performed and Revenue
(unaudited)
Three Months Ended March 31, 2026
2026
2025
% Change
Clinical including Pathline(1):
Number of tests performed
345,679
326,163
6.0
%
Average revenue/test
$
495
$
459
7.8
%
Clinical excluding Pathline(2):
Number of tests performed
335,155
326,163
2.8
%
Average revenue/test
$
501
$
459
9.2
%
_________________
(1)
Excludes tests and revenue related to non-clinical activity.
(2)
Excludes tests and revenue related to Pathline and non-clinical activity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260428135552/en/
Investor Contact
InvestorRelations@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Original: NeoGenomics Reports First Quarter 2026 Results
US Market News
5月前
NeoGenomics Reports Fourth Quarter and Full Year 2025 ResultsFebruary 17, 2026 7:05 AM
Business Wire
Full-year revenue increased 10% to $727 million;
Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition;
Successfully resolved RaDaR ST patent litigation
NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full-year results for the period ended December 31, 2025.
Fourth Quarter and Full Year 2025 Highlights
Fourth quarter consolidated revenue increased 11% to $190 million; Full-year consolidated revenue increased 10% to $727 million
Fourth quarter net loss decreased 36% to $10 million; Full-year net loss increased 37% to $108 million
Fourth quarter adjusted EBITDA(1) increased 13% to positive $13 million; Full year adjusted EBITDA increased 9% to positive $43 million
“We ended 2025 on a strong note, delivering double-digit revenue growth in the fourth quarter on the strength of our clinical volumes and ongoing mix shift toward higher value tests,” stated Tony Zook, CEO of NeoGenomics. “Notably, NGS grew 23% in Q4 and 22% for the full year, both well ahead of the market growth rate, reflecting our ability to successfully pull innovation through the community channel, where we enjoy a leadership position and where approximately 80% of all cancer care is delivered today.”
“Looking ahead, the imminent clinical launch of our RaDaR ST MRD assay further enhances our menu of advanced tests and allows us to address the $20+ billion molecular residual disease monitoring market. And while we anticipate modest revenue contribution from MRD in 2026, we believe the longer-term opportunity, in 2027 and beyond, is substantial. We believe RaDaR ST, together with our PanTracer family of therapy selection solutions, will be a key driver of our revenue growth over the long term. We envision a world where every cancer treatment decision is as personal as the patient, and this drives what we do every day. I am pleased with our progress in 2025 and excited about our current momentum.”
Fourth Quarter Results
Consolidated revenue for the fourth quarter of 2025 was $190 million, an increase of 11% over the same period in 2024. Average revenue per clinical test (“revenue per test”) increased by 5% to $488, with 7% growth excluding recently acquired Pathline tests. This increase reflects a shift toward higher-value tests, including NGS, and the positive impact of strategic reimbursement initiatives.
Consolidated gross profit for the fourth quarter of 2025 was $83 million, an increase of 8% compared to the fourth quarter of 2024. This increase was primarily due to an increase in revenue partially offset by higher compensation and benefit costs, and an increase in supplies costs. Consolidated gross profit margin(1), including amortization of acquired intangible assets and stock-based compensation expense, was 43.8%. Adjusted Gross Profit Margin(1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 46.4%.
Operating expenses for the fourth quarter of 2025 remained relatively flat at $97 million compared to the fourth quarter of 2024. Operating expenses included higher compensation and benefit costs offset by a decrease in restructuring charges due to the completion of the restructuring program in 2024.
Net loss for the quarter was $10 million compared to net loss of $15 million for the fourth quarter of 2024.
Adjusted EBITDA(1) was positive $13 million compared to positive $12 million in the fourth quarter of 2024. Adjusted Net Income(1) was $8 million compared to Adjusted Net Income(1) of $6 million in the fourth quarter of 2024.
Cash and cash equivalents totaled $160 million at quarter end.
Full Year Results
Consolidated revenue for 2025 was $727 million, an increase of 10% over 2024. This increase primarily reflects an increase in test volumes, a shift toward higher value tests, and the positive impact of strategic reimbursement initiatives. Revenues from the Pathline acquisition also contributed to revenue growth, which was partially offset by lower non-clinical revenue due to macro trends in the pharmaceutical and biotech industries, and a less favorable test mix. Net loss for 2025 was $108 million compared to net loss of $79 million in 2024. Adjusted EBITDA(1) for 2025 was positive $43 million compared to positive $40 million in 2024. Adjusted net income(1) for 2025 was $15 million compared to adjusted net income(1) of $14 million in 2024.
(1)
The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this report entitled “Use of Non-GAAP Financial Measures.” See also the tables reconciling such measures to their closest GAAP equivalent.
2026 Financial Guidance
The Company issued its full-year 2026 guidance(2) (in millions):
FY 2025
FY 2026 Guidance
YOY % Change from FY 2025
Actual
Low
High
Low
High
Consolidated revenue
$727
$793
$801
9%
10%
Net loss
$(108)
$(63)
$(50)
42%
54%
Adjusted EBITDA
$43
$55
$57
27%
31%
(2)
The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company’s securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.
Conference Call
The Company has scheduled a webcast and conference call to discuss its fourth quarter and full year 2025 results on Tuesday, February 17, 2026, at 8:30 a.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 825997. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
We routinely post information that may be important to investors on our website at https://www.neogenomics.com.
Forward Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include statements regarding the Company’s strategy, future operations, future financial position, future revenues, projected costs and capital expenditures, prospects and plans, estimates of market size and position, and objectives of Management. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
NeoGenomics, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands)
As of December 31,
2025
2024
ASSETS
Current Assets
Cash and cash equivalents
$
159,618
$
367,012
Marketable securities, at fair value
—
19,832
Accounts receivable, net
159,242
150,540
Inventories
28,566
26,748
Prepaid assets
21,443
20,165
Other current assets
7,417
11,722
Total current assets
376,286
596,019
Property and equipment (net of accumulated depreciation of $209,057 and $189,990, respectively)
84,834
94,103
Operating lease right-of-use assets
78,444
79,583
Intangible assets, net
286,528
339,681
Goodwill
524,344
522,766
Other assets
9,394
5,886
Total non-current assets
983,544
1,042,019
Total assets
$
1,359,830
$
1,638,038
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and other current liabilities
$
83,524
$
97,083
Current portion of operating lease liabilities
4,776
3,381
Current portion of convertible senior notes, net
—
200,777
Total current liabilities
88,300
301,241
Long-term liabilities
Operating lease liabilities
62,822
60,841
Convertible senior notes, net
341,858
340,335
Deferred income tax liabilities, net
18,219
21,510
Other long-term liabilities
12,069
11,772
Total long-term liabilities
434,968
434,458
Total liabilities
523,268
735,699
Stockholders’ equity
Total stockholders’ equity
836,562
902,339
Total liabilities and stockholders’ equity
$
1,359,830
$
1,638,038
NeoGenomics, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except per share amounts)
Three Months Ended December 31,
Years Ended December 31,
2025
2024
2025
2024
NET REVENUE
$
190,170
$
172,000
$
727,332
$
660,566
COST OF REVENUE
106,827
94,743
413,039
370,466
GROSS MARGIN
83,343
77,257
314,293
290,100
Operating expenses:
General and administrative
63,509
63,643
273,337
259,737
Research and development
9,179
7,969
37,077
31,159
Sales and marketing
23,443
22,339
92,007
84,652
Restructuring charges
—
1,707
—
6,658
Impairment charges
626
—
27,753
—
Total operating expenses
96,757
95,658
430,174
382,206
LOSS FROM OPERATIONS
(13,414
)
(18,401
)
(115,881
)
(92,106
)
Interest income
(1,523
)
(4,328
)
(9,070
)
(18,427
)
Interest expense
599
1,624
3,753
6,617
Other (income) expense, net
(84
)
431
(296
)
379
Loss before taxes
(12,406
)
(16,128
)
(110,268
)
(80,675
)
Income tax benefit
(2,525
)
(804
)
(2,243
)
(1,949
)
NET LOSS
$
(9,881
)
$
(15,324
)
$
(108,025
)
$
(78,726
)
NET LOSS PER SHARE
Basic
$
(0.08
)
$
(0.12
)
$
(0.84
)
$
(0.62
)
Diluted
$
(0.08
)
$
(0.12
)
$
(0.84
)
$
(0.62
)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic
128,648
127,160
128,101
126,658
Diluted
128,648
127,160
128,101
126,658
NeoGenomics, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
Years Ended December 31,
2025
2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
$
(108,025
)
$
(78,726
)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation
36,072
39,101
Amortization of intangibles
31,752
33,446
Stock-based compensation
41,316
33,413
Non-cash operating lease expense
6,752
8,926
Amortization of convertible debt discount
1,910
2,725
Amortization of debt issuance costs
87
189
Loss (gain) on disposal of assets, net
31
(49
)
Impairment charges
27,753
—
Impairment of long-lived assets
—
450
Other adjustments
(323
)
178
Changes in assets and liabilities, net:
(32,095
)
(32,630
)
Net cash provided by operating activities
$
5,230
$
7,023
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from maturities of marketable securities
20,060
53,916
Purchases of property and equipment
(27,008
)
(41,061
)
Proceeds from assets held for sale, net of closing costs
2,066
—
Business acquisitions, net of cash acquired
(6,454
)
—
Purchase of convertible note
(500
)
—
Purchase of equity securities
(500
)
—
Net cash (used in) provided by investing activities
$
(12,336
)
$
12,855
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock, net
962
4,646
Repayment of convertible debt
(201,250
)
—
Net cash (used in) provided by financing activities
$
(200,288
)
$
4,646
Net change in cash and cash equivalents
$
(207,394
)
$
24,524
Cash and cash equivalents, beginning of year
$
367,012
$
342,488
Cash, cash equivalents and restricted cash, end of year
$
159,618
$
367,012
Use of Non-GAAP Financial Measures
The Company reports its financial results in accordance with generally accepted accounting principles in the United States (“GAAP”). However, in order to provide greater transparency regarding our operating performance, the financial results and financial guidance in this press release refer to certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to the Company’s core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of the Company’s core test-level operating results across reporting periods. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results and may exclude items that are significant to understanding and assessing the Company's financial results. Therefore, should not be considered measures of liquidity or considered in isolation or as an alternative to other measures of the Company's profitability or performance under GAAP. The Company's presentation of non-GAAP financial measures is unlikely to be comparable to similarly-titled non-GAAP financial measures provided by other companies.
Definitions of Non-GAAP Financial Measures
Non-GAAP Adjusted EBITDA
“Adjusted EBITDA” is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest income, (ii) interest expense, (iii) tax (benefit) or expense, (iv) depreciation and amortization expense, (v) stock-based compensation expense, and, if applicable in a reporting period, (vi) CEO transition costs, (vii) acquisition and integration related expenses, (viii) restructuring charges, (ix) impairment charges, (x) intellectual property (“IP”) litigation costs, and (xi) other significant or non-operating (income) or expenses, net.
Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin
“Adjusted cost of revenue” is defined by NeoGenomics as cost of revenue before: (i) amortization of acquired intangible assets, and (ii) stock-based compensation expense.
“Adjusted gross profit” is defined by NeoGenomics as total revenue less adjusted cost of revenue.
“Adjusted gross profit margin” is defined by NeoGenomics as adjusted cost of revenue divided by total revenue.
Non-GAAP Adjusted Net (Loss) Income
“Adjusted net (loss) income” is defined by NeoGenomics as net (loss) income from continuing operations plus: (i) amortization of intangible assets, (ii) stock-based compensation expense, and, if applicable in a reporting period, (iii) CEO transition costs, (iv) acquisition and integration related expenses, (v) restructuring charges, (vi) impairment charges, (vii) IP litigation costs, and (viii) other significant or non-operating (income) or expenses, net. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method unless the effect of this adjustment on both the adjusted net (loss) income and weighted average diluted common shares outstanding would be anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method.
Non-GAAP Adjusted Diluted EPS
“Adjusted diluted EPS” is defined by NeoGenomics as adjusted net (loss) income divided by adjusted diluted shares outstanding. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted diluted shares outstanding will also include any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted diluted shares outstanding will exclude any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period.
The following tables present reconciliations of the Company’s non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP.
Reconciliation of GAAP Net Loss to Non-GAAP EBITDA and Adjusted EBITDA
(Unaudited, in thousands)
Three Months Ended December 31,
Years Ended December 31,
2025
2024
2025
2024
NET LOSS
$
(9,881
)
$
(15,324
)
$
(108,025
)
$
(78,726
)
Adjustments to net loss
Interest income
(1,523
)
(4,328
)
(9,070
)
(18,427
)
Interest expense
599
1,624
3,753
6,617
Income tax benefit
(2,525
)
(804
)
(2,243
)
(1,949
)
Depreciation
8,763
9,827
36,072
39,101
Amortization of intangibles
7,632
8,361
31,752
33,446
EBITDA (non-GAAP)
3,065
(644
)
(47,761
)
(19,938
)
Further adjustments to EBITDA:
CEO transition costs(1)
351
330
3,500
330
Acquisition and integration related expenses(2)
1,090
—
7,266
—
Stock-based compensation
8,042
8,328
41,316
33,413
Restructuring charges
—
1,707
—
6,658
Impairment charges(3)
626
—
27,753
—
IP litigation costs(4)
206
1,397
11,283
13,753
Other significant expenses, net(5)
—
755
—
5,392
Adjusted EBITDA (non-GAAP)
$
13,380
$
11,873
$
43,357
$
39,608
____________________
(1)
For the three months ended December 31, 2025, CEO transition costs include executive retention costs. For the year ended December 31, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. For the three months and year ended December 31, 2024, CEO transition costs include executive search costs.
(2)
For the three months and year ended December 31, 2025, acquisition and integration related expenses include consulting and legal fees, severance costs, and employee retention costs. There were no such costs for the three months and year ended December 31, 2024.
(3)
For the three months ended December 31, 2025, impairment charges include a loss on the sale of Trapelo Health, LLC assets. For the year ended December 31, 2025, impairment charges include losses from InVisionFirst®-Lung intangible asset impairment and inventory write-off, and an impairment loss on the sale of Trapelo Health, LLC assets. There were no such costs for the three months and year ended December 31, 2024.
(4)
For the three months ended December 31, 2025, IP litigation costs include legal fees. For the year ended December 31, 2025, IP litigation costs include a legal fees and a settlement payment. For the three months ended December 31, 2024, IP litigation costs include legal fees. For the year ended December 31, 2024, IP litigation costs include legal fees and a settlement payment.
(5)
For the three months ended December 31, 2024, other significant (income) expenses, net, includes site closure costs. For the year ended December 31, 2024, other significant (income) expenses, net, includes site closure costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three months and year ended December 31, 2025.
Reconciliation of Consolidated GAAP Cost of Revenue, Gross Profit and Gross Profit Margin to
Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin
(Unaudited, dollars in thousands)
Three Months Ended December 31,
Years Ended December 31,
2025
2024
% Change
2025
2024
% Change
Consolidated:
Total revenue (GAAP)
$
190,170
$
172,000
10.6
%
$
727,332
$
660,566
10.1
%
Cost of revenue (GAAP)
$
106,827
$
94,743
12.8
%
$
413,039
$
370,466
11.5
%
Adjustments to cost of revenue(1)
(4,964
)
(5,292
)
(20,353
)
(21,127
)
Adjusted cost of revenue (non-GAAP)
$
101,863
$
89,451
13.9
%
$
392,686
$
349,339
12.4
%
Gross profit (GAAP)
$
83,343
$
77,257
7.9
%
$
314,293
$
290,100
8.3
%
Adjusted gross profit (non-GAAP)
$
88,307
$
82,549
7.0
%
$
334,646
$
311,227
7.5
%
Gross profit margin (GAAP)
43.8
%
44.9
%
43.2
%
43.9
%
Adjusted gross profit margin (non-GAAP)
46.4
%
48.0
%
46.0
%
47.1
%
____________________
(1)
Cost of revenue adjustments for the three months ended December 31, 2025 includes $4.6 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Cost of revenue adjustments for the three months ended December 31, 2024 includes $4.9 million of amortization of acquired intangible assets and $0.4 million of stock-based compensation. Cost of revenue adjustments for the year ended December 31, 2025 includes $18.9 million of amortization of acquired intangible assets and $1.4 million of stock-based compensation. Cost of revenue adjustments for the year ended December 31, 2024 includes $19.6 million of amortization of acquired intangible assets and $1.4 million of stock-based compensation.
Reconciliation of GAAP Net Loss to Non- GAAP Adjusted Net Loss and
GAAP EPS to Non-GAAP Adjusted EPS
(Unaudited, in thousands, except per share amounts)
Three Months Ended December 31,
Years Ended December 31,
2025
2024
2025
2024
Net loss (GAAP)
$
(9,881
)
$
(15,324
)
$
(108,025
)
$
(78,726
)
Adjustments to net loss:
Amortization of intangibles
7,632
8,361
31,752
33,446
CEO transition costs(1)
351
330
3,500
330
Acquisition and integration related expenses(2)
1,090
—
7,266
—
Stock-based compensation expense
8,042
8,328
41,316
33,413
Restructuring charges
—
1,707
—
6,658
Impairment charges(3)
626
—
27,753
—
IP litigation costs(4)
206
1,397
11,283
13,753
Other significant expenses, net(5)
—
755
—
5,392
Adjusted net income (non-GAAP)
$
8,066
$
5,554
$
14,845
$
14,266
Net loss per diluted share (GAAP)
Diluted EPS
$
(0.08
)
$
(0.12
)
$
(0.84
)
$
(0.62
)
Adjustments to net loss per diluted share:
Amortization of intangibles
0.06
0.07
0.25
0.26
CEO transition costs(1)
—
—
0.03
—
Acquisition and integration related expenses(2)
0.01
—
0.06
—
Stock-based compensation expense
0.06
0.07
0.32
0.26
Restructuring charges
—
0.01
—
0.05
Impairment charges(3)
—
—
0.22
—
IP litigation costs(4)
—
0.01
0.09
0.11
Other significant expenses, net(5)
—
0.01
—
0.05
Rounding and impact of diluted shares in adjusted diluted share(6)
0.01
(0.01
)
(0.01
)
—
Adjusted diluted EPS (non-GAAP)
$
0.06
$
0.04
$
0.12
$
0.11
Weighted average shares used in computation of adjusted diluted EPS:
Diluted common shares (GAAP)
128,648
127,160
128,101
126,658
Dilutive effect of options, restricted stock, and converted shares(7)(8)
—
—
—
—
Adjusted diluted shares outstanding (non-GAAP)
128,648
127,160
128,101
126,658
____________________
(1)
For the three months ended December 31, 2025, CEO transition costs include executive retention costs. For the year ended December 31, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. For the three months and year ended December 31, 2024, CEO transition costs include executive search costs.
(2)
For the three months and year ended December 31, 2025, acquisition and integration related expenses include consulting and legal fees, severance costs, and employee retention costs. There were no such costs for the three months and year ended December 31, 2024.
(3)
For the three months ended December 31, 2025, impairment charges include a loss on the sale of Trapelo Health, LLC assets. For the year ended December 31, 2025, impairment charges include losses from InVisionFirst®-Lung intangible asset impairment and inventory write-off, and an impairment loss on the sale of Trapelo Health, LLC assets. There were no such costs for the three months and year ended December 31, 2024.
(4)
For the three months ended December 31, 2025, IP litigation costs include legal fees. For the year ended December 31, 2025, IP litigation costs include a legal fees and a settlement payment. For the three months ended December 31, 2024, IP litigation costs include legal fees. For the year ended December 31, 2024, IP litigation costs include legal fees and a settlement payment.
(5)
For the three months ended December 31, 2024, other significant (income) expenses, net, includes site closure costs. For the year ended December 31, 2024, other significant (income) expenses, net, includes site closure costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three months and year ended December 31, 2025.
(6)
This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive or GAAP net (loss) income is positive and adjusted net (loss) income is negative, also compensates for the effects of additional diluted shares included or excluded in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes.
(7)
In those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive.
(8)
In those periods in which GAAP net (loss) income is positive and adjusted net (loss) income is negative, this adjustment excludes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period.
Reconciliation of Non-GAAP Financial Guidance to Corresponding GAAP Measures
(Unaudited, in thousands, except per share amounts)
GAAP net loss in 2026 will be impacted by certain charges, including: (i) expense related to the amortization of intangible assets, (ii) stock-based compensation, and (iii) other one-time expenses. These charges have been included in GAAP net loss available to stockholders and GAAP net loss per share; however, they have been removed from adjusted net loss and adjusted diluted net loss per share.
The following table reconciles the Company’s 2026 outlook for net loss and EPS to the corresponding non-GAAP measures of adjusted net loss, adjusted EBITDA, and adjusted diluted EPS:
Year Ended December 31, 2026
Low Range
High Range
Net loss (GAAP)
$
(63,000
)
$
(50,000
)
Amortization of intangibles
30,000
30,000
Stock-based compensation
43,000
40,000
Other one-time expenses
11,000
7,000
Adjusted net income (non-GAAP)
21,000
27,000
Interest and taxes
(5,000
)
(6,000
)
Depreciation
39,000
36,000
Adjusted EBITDA (non-GAAP)
$
55,000
$
57,000
Net loss per diluted share (GAAP)
$
(0.48
)
$
(0.38
)
Adjustments to net loss per diluted share:
Amortization of intangibles
0.23
0.23
Stock-based compensation
0.33
0.31
Other one-time expenses
0.08
0.05
Rounding and impact of diluted shares in adjusted diluted shares(1)
—
—
Adjusted diluted EPS(2) (non-GAAP)
$
0.16
$
0.21
Weighted average assumed shares outstanding in 2026:
Diluted shares (GAAP)
130,000
130,000
Options, restricted stock, and converted shares not included in diluted shares(2)
—
—
Adjusted diluted shares outstanding (non-GAAP)
130,000
130,000
____________________
(1)
This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, also compensates for the effects of additional diluted shares included in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes.
(2)
For those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive.
Supplemental Information
Clinical Tests Performed and Revenue
(Unaudited)
Three Months Ended December 31,
Years Ended December 31,
2025
2024
% Change
2025
2024
% Change
Clinical including Pathline(1):
Number of tests performed
356,136
321,679
10.7
%
1,399,703
1,248,740
12.1
%
Average revenue/test
$
488
$
465
4.9
%
$
471
$
457
3.1
%
Clinical excluding Pathline(2):
Number of tests performed
342,586
321,679
6.5
%
1,358,969
1,248,740
8.8
%
Average revenue/test
$
496
$
465
6.7
%
$
476
$
457
4.2
%
____________________
(1)
Excludes tests and revenue related to non-clinical activity.
(2)
Excludes tests and revenue related to Pathline and non-clinical activity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260217513962/en/
Investor Contact
Kendra Webster
InvestorRelations@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Original: NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
Hot Features
プレミアム
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
iHub News
2月前
EarningsCentral
4月前
tw0122
10月前
Monksdream
2年前
rusty8350
3年前
conix
4年前
Armed n Hammered
5年前
headsortails2066
7年前
ValueInvestor15
9年前
thetechtrader
11年前
magness
11年前
メールアドレスで登録
